EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

History matters: Preventing severe allergic transfusion reactions

Edina A Wappler-Guzzetta, Asad Shafiq, Umaima Asad, Tushar Chakravarty, Elena G Nedelcu

American Journal of Clinical Pathology · 2025

DOI: 10.1093/ajcp/aqaf093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Edina A Wappler-Guzzetta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States. Hauptthemen laut MEDLINE: Transfusion Reaction, Anti-Allergic Agents, Hypersensitivity. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Prior studies have shown that pretransfusion medication is not effective in preventing allergic transfusion reactions (ATRs), but these studies did not consider the patient’s history of ATR. This study evaluated whether pretransfusion antiallergy medications decrease the chance of ATRs in patients with a history of severe ATR.

Methods

This single-center, retrospective study investigated the effect of pretransfusion medications on preventing ATRs in patients with a history of at least 1 severe ATR between March 2018 and January 2024. Patient demographics as well as clinical and transfusion reaction data were collected from our electronic health record (EHR) system. Data were analyzed using SPSS (IBM Corp) and machine learning in Python, version 3.12.4.

Results

In our cohort, 53 patients aged 5 weeks to 94 years with 2767 analyzable transfusion encounters had experienced 88 lifelong mild and severe ATRs. Premedication (P = .021), regular antiallergy medication (P < .001), and washing/volume reduction (P = .032) were associated with a statistically significantly lower chance of developing ATRs in our patient population.

Conclusions

Patients with at least 1 severe ATR benefit from pretransfusion administration of antiallergy medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transfusion ReactionAnti-Allergic AgentsHypersensitivityRetrospective StudiesHumansElectronic Health RecordsMaleFemaleYoung AdultAdultMiddle AgedMachine LearningInfantChild, PreschoolChildAdolescentTreatment Outcome

Stichwörter der Autor:innen

allergic transfusion reactionspretransfusion medicationsretrospective study

Substanzen

Anti-Allergic Agents

Autor:innen und Institutionen

  • Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
  • College of Business and Economics, California State University Fullerton, Fullerton, CA, United States.
  • Centennial High School, Corona, CA, United States.
  • Department of Pathology and Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.

Zitieren

APA

Wappler-Guzzetta, E. A., Shafiq, A., Asad, U., Chakravarty, T., & Nedelcu, E. G. (2025). History matters: Preventing severe allergic transfusion reactions. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqaf093

Vancouver

Wappler-Guzzetta EA, Shafiq A, Asad U, Chakravarty T, Nedelcu EG. History matters: Preventing severe allergic transfusion reactions. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqaf093

BibTeX
@article{WapplerGuzzetta2025,
  author = {Wappler-Guzzetta, Edina A and Shafiq, Asad and Asad, Umaima and Chakravarty, Tushar and Nedelcu, Elena G},
  title = {History matters: Preventing severe allergic transfusion reactions},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  doi = {10.1093/ajcp/aqaf093}
}
Kostenlos starten →